ELI
OCUL icon

Empire Life Investments’s Ocular Therapeutix OCUL Stock Holding History

Empire Life Investments’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.56M Sell
871,692
-12,605
-1% -$114K 0.48% 58
2026
Q1 		$7.37M Buy
884,297
+344,182
+64% +$3.28M 0.45% 59
2025
Q4 		$6.56M Buy
540,115
+288,853
+115% +$3.51M 0.37% 63
2025
Q3 		$2.94M Buy
+251,262
New +$3M 0.17% 83

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Empire Life Investments's OCUL Position: Q2 2026 in Review

Empire Life Investments reduced its Ocular Therapeutix (OCUL) stake by 1.4% in Q2 2026, selling an estimated $114K and leaving 871,692 shares worth $8.56M. The position accounts for 0.48% of the portfolio, ranked #58.

Empire Life Investments first reported a position in OCUL in Q3 2025 and has held it in 4 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Empire Life Investments held 871,692 shares of Ocular Therapeutix worth $8.56M as of Q2 2026.
  • Empire Life Investments sold 12,605 Ocular Therapeutix shares in Q2 2026, an estimated $114K.
  • Ocular Therapeutix made up 0.48% of Empire Life Investments's portfolio in Q2 2026, its #58 holding.
  • Empire Life Investments first reported a position in Ocular Therapeutix in Q3 2025 and has held it in 4 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Empire Life Investments's 13F filing for Q2 2026, filed 24 Jul 2026.